JOUNCE THERAPEUTICS INC (JNCE) Stock News
NASDAQ:JNCE - Nasdaq - US4811161011 - Common Stock - Currency: USD
JNCE Latest News, Press Relases and Analysis
Jounce Therapeutics Announces Closing of Tender Offer
Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights...
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, USX, JNCE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Top 5 Health Care Stocks That May Crash In March
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Why Is Boxed (BOXD) Stock Down 41% Today?
Boxed (BOXD) stock is falling hard on Wednesday after the company floated the possibility of a bankruptcy filing to investors.
Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?
Jounce Therapeutics (JNCE) stock is climbing higher on Wednesday after getting an unexpected acquisition bid from Concentra Biosciences.
Mentions: AMC
Jounce stock jumps as Concentra agrees to buy (NASDAQ:JNCE)
Jounce Therapeutics (JNCE) announced that Concentra Biosciences agreed to acquire it for $1.85 in cash per share plus a contingent value right ((CVR)). Read more here.
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...
Moore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JNCE, ADAP, TCRR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Why Is Inpixon (INPX) Stock Down 34% Today?
Inpixon (INPX) stock is falling on Wednesday after the company announced the merger of subsidiary CXApp with KINS Technology Group.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning!
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...
INVESTIGATION ALERT: Halper Sadeh LLC Investigates INDT, FOCS, JNCE, PTRS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Moore Kuehn Encourages ROCC, JNCE, BRMK, and FOCS Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PTRS, JNCE, INFI, HRZN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Jounce Therapeutics downgraded to market perform at Raymond James (NASDAQ:JNCE)
Raymond James has downgraded Jounce Therapeutics (JNCE) to market perform from outperform saying that the biotech's Wednesday announcement of a restructuring has led to removal of...
Mentions: RJF
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNKB, PTRS, JNCE, MEIP
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder Alert: Ademi LLP investigates whether Jounce Therapeutics, Inc. has obtained a Fair Price in its transaction with RedX Pharma
/PRNewswire/ -- Ademi LLP is investigating Jounce (NASDAQ: JNCE) for possible breaches of fiduciary duty and other violations of law in its transaction with...